Navigation Links
ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
Date:12/16/2009

lant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

    For further information please contact:

    ThromboGenics

    Dr. Patrik De Haes, CEO                   Tel: +32-16-75-13-10
                                              patrik.dehaes@thrombogenics.com

    Dr. Steve Pakola, CMO                     Tel: +1-212-201-0920
                                              steve.pakola@thrombogenics.com

    Citigate Dewe Rogerson

    Amber Bielecka/David Dible/Nina Enegren   Tel: +44(0)207-638-95-71
                                              '/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
9. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
10. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... HILL, N.C. , Dec. 23, 2014  Medical ... success. As the key link between the medical device ... grow even more in the coming years as the ... According to research by benchmarking firm, ... MSLs can gain an important edge is by harnessing ...
(Date:12/22/2014)... VIEJO, Calif. , Dec. 22, 2014 ... into expanded corporate offices in Aliso Viejo ... announced that due to the tremendous growth and worldwide ... needed. Sales of patented SnoreRx, the anti snore cure ... offices. He said, "We are now in 23 ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and ... the addition of the "Investment Analysis of ... to their offering. ... in the US medical device sector identifies the ... and venture capital investments, and mergers and acquisitions. ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2Investment Analysis of the US Medical Device Sector 2
... Safety Concerns Raised ... NEW YORK, Dec. 5 Keryx Biopharmaceuticals,(Nasdaq: KERX ... (DSMC) responsible for monitoring Sulonex(TM) (sulodexide oral,gelcaps), the Company,s ... nephropathy, recently met to evaluate the data from,the ongoing ...
... N.J., Dec. 5 Senesco,Technologies, Inc. ("Senesco" or ... it has initiated preclinical lab studies at Mayo ... test the ability of,Senesco,s Factor 5A gene technology ... will evaluate delivery molecules for,encapsulation of Factor 5A ...
Cached Medicine Technology:Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data 2Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data 3Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data 4Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data 5Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data 6Senesco Technologies Initiates Preclinical Studies for Cancer Target 2
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... wheat that boosts up the protein, zinc and iron ... that affect millions of children worldwide. Researchers at the ... the U.S. Department of Agriculture; and the University of ... the Nov. 24 issue of the journal Science. ...
... there is one more impact of a job burn out. ... also stir up a host of ailments, say Scientists. //This ... stress at work can contribute to high blood pressure, metabolic ... 677 workers in Israel revealed that risk of Type 2 ...
... School of Medicine have reported that genetics has a ... preemies//, a disease known to hamper the development of ... This report is published in the November issue of ... show that genetic factors are a significant component of ...
... Scientists at San Francisco, in the US, have announced ... positive results. // ,This treatment referred to as ... of brain cancer, termed glioma.Scientists at the University of ... mode of treatment involves isolating a protein gp96 from ...
... Vietnam, The Nha Trang Institute of Vaccines and Biological ... 5,000 doses of a H5N1 vaccine for// humans from ... on white mice, guinea-pigs and cockerels and similar reactions ... Institute of Verification of Vaccines and Biological Products. Its ...
... Michelle Hasni of Cutler Ridge, Miami, delivered a male child ... very rare congenital heart disorder called Ectopia// cordis. Seven or ... defect. ,The baby named Naseem, was born with ... and the protective cover for the heart called pericardium had ...
Cached Medicine News:Health News:Newly Cloned Wheat Gene May Boosts Foods' Nutrient Contents – Says A Researc 2Health News:Genetics Plays A Crucial Role In Preemies' Destructive Eye Disease 2Health News:Naseem’s Heart Put In Its Plac 2
... Size: 5.0 x 2.5 x 80 mm. Half ... by Harvey A. Lincoff, M.D. has been modified ... design. The material is a closed cell sponge ... with rounded edges to minimize scleral intrusion. These ...
... mm. Storz offers the original Scleral ... A. Lincoff, M.D. The material is ... non-toxic and non-antigenic. Implants are soft ... intrusion. These implants are packaged sterile ...
For use under curved implants. Indications: When additional buckling is required in the meridional direction. Overall length: 15.0 mm....
For use under silicone strips E5381 610, E5381 611 and E5381 710. Indications: When higher buckle is required. Overall length: 6.1 mm....
Medicine Products: